A 25-Year-Old Argentine Biologist Is Developing an Injectable Gel That Could Help Repair Hearts After a Heart Attack

At just 25 years old, Argentine biologist Pilar Ferrer is helping pursue an idea that sounds as though it belongs in a science-fiction film: an injectable gel designed to help damaged heart tissue recover after a heart attack.

The concept is remarkable in its simplicity. Rather than replacing an injured heart or relying exclusively on treatments that manage the consequences of heart damage, researchers are exploring whether a specially designed biomaterial could be placed directly into the damaged area and create conditions that support the heart's natural healing processes.

The experimental material is a bioactive hydrogel inspired by the amniotic membrane, a thin biological layer associated with the placenta. Researchers are investigating how components of this tissue might be used to create a supportive environment for injured cardiac muscle.

Ferrer is part of a wider scientific effort involving cardiovascular research, regenerative medicine, and biomaterials. The project grew out of research associated with Favaloro University and Argentina's National Scientific and Technical Research Council, known as CONICET, and is now being developed toward a potential future medical application.

The ambition is significant because a heart attack can leave lasting damage. When blood flow to part of the heart is interrupted, heart muscle cells may die. The body responds by repairing the injured area, but the replacement tissue often becomes a scar rather than functioning muscle capable of contracting normally.

That scar can affect how efficiently the heart pumps blood, and some patients develop progressive changes in the heart's structure and function.

The Argentine research team hopes that a bioactive hydrogel could help address part of this problem by providing a more favorable environment within the injured tissue.

However, an important distinction must be made from the beginning: the gel is experimental, not an approved treatment, and it has not yet been established as a safe and effective therapy for people.

The research remains at the preclinical stage, meaning that laboratory and animal studies must provide sufficient evidence before clinical testing in humans can be considered.

Even so, the project represents an intriguing direction in regenerative medicine. It brings together a young scientist's work, an unusual biological material, and a medical challenge that researchers around the world have been trying to solve for decades.

The Young Scientist Behind the Research

Pilar Ferrer is an Argentine biologist who graduated in Biological Sciences from Favaloro University. She has worked in cardiovascular regenerative medicine and pursued doctoral research focused on the potential of amniotic membrane-derived materials to support heart repair.

Her work is part of a multidisciplinary effort rather than an independent invention developed by one person. The project involves researchers with expertise in biology, cardiovascular physiology, biotechnology, and biomaterials.

The broader research team has included Daniela Olea, a biotechnology researcher who has supervised Ferrer's doctoral work, along with other specialists involved in studying the biological properties of amniotic membrane and its possible applications in damaged cardiac tissue.

In 2025, the team received a special mention in Argentina's César Milstein Award program for research concerning the cardiorregenerative potential of decellularized human amniotic membrane in a preclinical model of acute myocardial infarction.

That recognition reflected the scientific interest in the underlying research, although an award does not establish that an experimental treatment is effective in patients.

As the project developed, the researchers also began exploring how their findings might eventually be translated into a practical therapeutic product. The biotechnology venture Amnova Biotech emerged from this effort, with Ferrer taking a leadership role alongside other members of the team.

The transition from an academic research project to a potential medical technology introduces a new set of challenges. A promising material must not only demonstrate biological activity in controlled experiments; it must also be manufactured consistently, meet appropriate quality standards, undergo extensive safety testing, and satisfy regulatory requirements.

These steps can take years, and many experimental therapies never progress to routine clinical use.

Nevertheless, Ferrer's involvement illustrates an important part of modern biomedical research: young scientists can contribute to ambitious projects by combining specialized knowledge with collaboration across different disciplines.

The most important question is not simply how old the researcher is. It is whether the scientific idea can withstand careful testing and eventually provide a meaningful benefit to patients.

In this case, the team is investigating whether a material inspired by the placenta could help create better conditions for the injured heart to heal.

Why a Heart Attack Can Leave Permanent Damage

To understand the promise of the hydrogel, it helps to understand what happens during a heart attack.

A heart attack, medically known as a myocardial infarction, occurs when blood flow to part of the heart muscle is severely reduced or blocked. In many cases, a blood clot forms in a coronary artery that has already been narrowed by the buildup of fatty deposits.

Without an adequate supply of oxygen, the affected heart muscle begins to suffer injury. If circulation is not restored quickly, some of those cells die.

The consequences depend on several factors, including the size and location of the damaged area, how quickly treatment begins, and the patient's overall cardiovascular health.

Emergency treatment aims to restore blood flow as rapidly as possible, limit further injury, and prevent complications. Depending on the circumstances, treatment may involve procedures to reopen a blocked artery, medication, and other forms of cardiovascular care.

Modern medicine has made major advances in treating acute heart attacks. Yet restoring blood flow does not necessarily bring every damaged heart muscle cell back to life.

Once a significant area of cardiac muscle has died, the body generally repairs it through a process involving inflammation, the removal of damaged material, and the formation of scar tissue.

Scar formation is part of the body's response to injury. It helps stabilize the damaged area and prevent the heart wall from rupturing. But scar tissue does not behave like healthy cardiac muscle.

Normal heart muscle contains specialized cells called cardiomyocytes, which contract in a coordinated way to pump blood throughout the body. Mature human cardiomyocytes have only a limited capacity to regenerate after substantial injury.

As a result, scar tissue may remain where functioning muscle once existed.

The American Heart Association explains that heart attacks can damage the heart muscle and that the extent of injury depends partly on how long blood flow is interrupted. Damaged muscle can affect pumping ability and contribute to heart failure in some patients.

For certain people, the effects extend well beyond the initial emergency. They may experience reduced exercise tolerance, persistent fatigue, shortness of breath, or other symptoms associated with impaired heart function.

Others recover well with prompt treatment, medication, cardiac rehabilitation, and appropriate long-term management.